Siemens Healthcare has received FDA 501(k) marketing clearance for a software package that helps in the assessment of cerebral blood flow during interventional procedures.
Siemens Healthcare has received FDA 501(k) marketing clearance for a software package that helps in the assessment of cerebral blood flow during interventional procedures.
The syngo Neuro PBV IR (Parenchymal Blood Volume Interventional Radiology) is intended to provide visual assistance in diagnosis and treatment of vessel malformations, such as aneurysms, arteriovenous malformations, and stenosis, the company said. The software displays a color-coded map of cerebral tissue in the angiography suite, which can help in the treatment of stroke patients.
Syngo Neuro PBV uses cone-beam computed tomography (CT) to produce a qualitative colorized image similar to CT perfusion, the company said. It is designed for the visualization of contrast-enhanced blood distribution in the arterial and venous vessels in the head using color-coded relative values for diagnosis.
Parenchymal blood volume information is acquired with two C-arm rotations around the patient and a steady-state contrast injection. The system then applies processing algorithms to generate a neurological PBV map, according to the company.
“Neurovascular imaging has evolved from simple anatomical 2D rendition of blood vessels to 3D spatial visualization and, with the Neuro PBV, to physiological functional imaging of the brain,” Michel E. Mawad, MD, Baylor College of Medicine, Houston, said in the company’s press release. “Neuro PBV is a promising technique that will add valuable information about the viability of the brain and should help guide the interventionalist in the decision-making process of revascularization procedures."
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.